A Phase 1 Study to Evaluate the Safety of OBP-301, Telomelysin in Combination With Radiation Therapy in Patients With Esophageal Cancer Not Applicable for Standard Therapy
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2018
Price : $35 *
At a glance
- Drugs Telomelysin (Primary)
- Indications Oesophageal cancer
- Focus Adverse reactions
- Sponsors Oncolys BioPharma
- 24 Sep 2018 Planned End Date changed from 1 Oct 2018 to 1 Jun 2019.
- 24 Sep 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Mar 2019.
- 26 Mar 2018 According to an Oncolys BioPharma media release, three patients have been enrolled in Cohort 1 with lower dose administration since July 2017.